Stanford discovers brain-targeted peptide rivaling Ozempic without side effects; CNN publishes comprehensive peptide guide; tirzepatide outperforms semaglutide at 12 months.
12 stories · Covering research, industry, clinical-trials, regulatory
Today's peptide news is anchored by a potentially paradigm-shifting discovery from Stanford: an AI-identified natural peptide called BRP that targets the hypothalamus directly to suppress appetite — achieving Ozempic-like weight loss in mice without the nausea, constipation, or muscle loss that plague current GLP-1 drugs. If it translates to humans, it could upend the $100B+ obesity drug market. Meanwhile, CNN published its most comprehensive peptide guide yet, Peter Attia devoted a full podcast episode to separating peptide science from hype, and new real-world data presented at the Obesity Medical Association conference confirmed tirzepatide's superiority over semaglutide at 12 months. The day's coverage reflects a maturing field where blockbuster commercial launches (Foundayo projected for 5M+ prescriptions), evolving clinical evidence (GLP-1s cutting heart failure hospitalization by 40%), and persistent safety concerns all compete for attention.
Stanford scientists used AI to identify BRP, a naturally occurring peptide that acts directly on the hypothalamus to suppress appetite — avoiding the gut-related side effects of current GLP-1 drugs. In animal studies, BRP reduced body weight and fat without nausea, constipation, or muscle loss. Published in Nature, with human trials planned.
CNN published a comprehensive consumer guide distinguishing FDA-approved peptide therapeutics from unregulated wellness peptides. Experts warn that rising demand is fueling an online black market with unknown safety risks, while HHS Secretary RFK Jr. pushes to relax restrictions.
A poster at the Obesity Medical Association annual conference (April 10-12, San Diego) showed tirzepatide achieved greater body weight reduction than semaglutide at 12 months in a real-world Truveta EHR analysis of adults with obesity without diabetes, consistent with SURMOUNT-5 clinical trial results.
Peter Attia devoted a full AMA episode to peptides, building a framework for evaluating any compound based on mechanism, evidence quality, and safety. The episode examines BPC-157, SS-31, melanotan-II, and CJC-1295, addresses grey-market risks, and maps which areas of medicine stand to benefit most.
A comprehensive review by D.J. Drucker in Nature Medicine outlines GLP-1 medicines expanding beyond diabetes and obesity into cardiovascular disease, neurodegenerative disorders, substance use, metabolic liver disease, arthritis, type 1 diabetes, and inflammatory bowel disease. New multi-agonist molecules with optimized pharmacokinetics are producing greater weight loss.
UBS analysts forecast 5-6 million Foundayo prescriptions in 2026, projecting roughly $2 billion in launch-year sales. RBC Capital Markets projects peak annual US sales of $36 billion. Eli Lilly pre-stocked $1.5 billion of inventory ahead of the April 6 retail launch.
The American Diabetes Association published new pharmacologic obesity treatment standards in its journal Diabetes, Obesity, and Cardiometabolic Care, calling on clinicians and policymakers to eliminate weight stigma. Over 40% of people with class II obesity report weight-based discrimination that impedes treatment access.
The Week reports that India's GLP-1 market is surging following semaglutide patent expiry in March, with doctors warning that self-medication — particularly through unapproved online channels — poses serious risks including pancreatitis and thyroid complications. Experts emphasize the need for clinical oversight and proper dose titration.
A Mass General Brigham study of over 90,000 HFpEF patients published in JAMA found semaglutide reduced heart failure hospitalization or all-cause mortality by 42%, while tirzepatide achieved a 58% risk reduction compared with sitagliptin. Both drugs showed acceptable safety profiles with benefits appearing early in treatment.
A study in Scientific Reports found that early intervention with tirzepatide or semaglutide significantly reduced atherosclerotic plaque formation in ApoE-knockout mice, suggesting GLP-1 drugs may have preventive cardiovascular benefits beyond their metabolic effects when initiated before disease progression.
BASF launched NeoHelix Regenerate, a precision peptide developed with U.S. startup 3Helix that targets damaged collagen for renewal. A 56-day clinical study showed a 41% reduction in damaged collagen and 65% increase in hyaluronic acid levels. BASF also introduced SkinNexus Collag3n, a bio-identical recombinant Collagen III fragment produced via vegan yeast fermentation.
A comprehensive review in Journal of Nanobiotechnology positions peptide-drug conjugates (PDCs) as the next evolution beyond antibody-drug conjugates (ADCs) for targeted cancer therapy. Six PDCs are now in Phase III clinical trials with approximately 96 in development, offering advantages in tissue penetration, lower immunotoxicity, and more accessible manufacturing than ADCs.